Teriparatide for bone loss in the jaw.
Andrew
A
Grey
D019386:Alendronate / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D003131:Combined Modality Therapy; D006801:Humans; D007568:Jaw / Q000502:physiology*; D007571:Jaw Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy*; D010518:Periodontitis / Q000188:drug therapy* / Q000601:surgery; D019379:Teriparatide / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D019379:Teriparatide; D019386:Alendronate